LATEST ALERTS
The cannabinoid sector is unlikely to find an ally in new US surgeon general nominee Casey Means, but she could help further progress towards a viable commercial psychedelics market in the country
The United Nations Commission on Narcotic Drugs voted on 12th March to classify HHC as a banned substance, with an aim of restricting and controlling the use of the cannabinoid at an international level
This report examines products offered online in the US that contain alternative active ingredients, such as intoxicating hemp-derived cannabinoids (IHDCs), kratom and mushrooms
Cannabinoids have been credited with many benefits to individual health. But now industry stakeholders are wondering if the hemp plant could be applied to an even bigger task – saving the planet
Canadian advocates for therapeutic access to psilocybin are ramping up their efforts to get the federal government to grant exemptions to the country’s drug laws so patients and healthcare providers can legally access the drug
A measure to allow the use of psychedelics in Colorado is a major step – but supporters worry it could lead to the sort of bad experience that would set back the progress of legalisation
It is not only cannabis that is attracting what might be thought unexpected investment and support from traditionally conservative, right-wing supporters and lobbyists in the US
Drug legalisation as an issue truly does bring together some strange bedfellows – like the Navajo Nation and drug prohibitionists
As debate over the legalisation of recreational cannabis involves a growing number of European countries, the commercial demand for legal psychoactive alternatives to controlled cannabinoid variants is on the rise
A new conceptual inhaler designed around the idea of controlled microdosing could eventually lead to a product capable of administering precise amounts of active ingredients such as CBD, nicotine or even psychedelics
The US Drug Enforcement Administration (DEA) has withdrawn its proposal to effectively ban five psychedelic compounds after receiving significant opposition from the research and advocacy community
Psychedelics are having another moment in the spotlight. But is the heightened awareness just hype, or have these once-taboo substances been permanently rehabilitated?
Biotechnology firm Awakn Life Sciences has secured UK government funding to accelerate the route to the UK and US markets for its proprietary ketamine-assisted therapy, which is designed to treat alcohol use disorder
As the first federally approved psychedelics clinical trial begins in the US, there is broad but not total agreement among official bodies over legalising research into hallucinogenic substances
Strangely, Brexit and then the Covid-19 pandemic have combined to create ideal conditions for the UK to potentially become a leader in psychedelics research
Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.
"*" indicates required fields
Notifications
